Alterity Therapeutics Limited (NASDAQ:ATHE) is one of the best performing ASX stocks in 2025. On September 15, the company shared data from its Phase 2 clinical trial of the drug ATH434-201 at the ...

After menopause, women with MS show accelerated loss of volume in brain structures associated with memory, attention, and problem-solving.

The latest announcement is out from Alterity Therapeutics ( (AU:ATH) ).

Alterity Therapeutics has shown its Multiple System Atrophy drug ATH-434 has a potential market value of US$2.4 billion if approved. ... Read More The post StockTake: Alterity’s ATH434 shows US$2.4b ...

See why Teva Pharmaceutical Industries Limited is shifting the CNS market with Austedo sales growth, new clinical data, and ...

Hameroff points to studies that demonstrate that, in humans, applying sub-thermal tFUS to the hippocampus of Alzheimer’s ...

PACB expands its PureTarget portfolio, streamlining carrier screening with HiFi sequencing to meet rising global demand.

Explore the Fight Retinal Blindness! Project, a global registry enhancing VEGF inhibitor treatment outcomes with ...

A children's social worker remembers their former team manager, who was instrumental in supporting her team during the ...

The ASX closed 0.16% lower on September 30, 2025 after the RBA kept the cash rate on hold at 3.6% at its latest meeting.

The human body requires protein as one of its fundamental nutritional elements, and it is known as the 'building block of the ...

Clinical, neuroimaging, and fluid biomarker trajectories over 3 years suggested slow but evident brain recovery in a small ...